Show simple item record

dc.contributor.authorButi, M.
dc.contributor.authorFlisiak, R.
dc.contributor.authorRasenack, J.
dc.contributor.authorDavis, G.
dc.contributor.authorAlberti, A.
dc.contributor.authorGoeser, T.
dc.contributor.authorStanciu, C.
dc.contributor.authorChuang, W. -L.
dc.contributor.authorKao, J. -H.
dc.contributor.authorStreinu-Cercel, A.
dc.contributor.authorHofstetter, G.
dc.contributor.authorWang, J.
dc.contributor.authorAvila, C.
dc.contributor.authorOrsenigo, R.
dc.contributor.authorTabak, F.
dc.date.accessioned2021-03-04T07:58:58Z
dc.date.available2021-03-04T07:58:58Z
dc.identifier.citationButi M., Flisiak R., Rasenack J., Davis G., Alberti A., Goeser T., Stanciu C., Chuang W. -. , Tabak F., Kao J. -. , et al., "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)", International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58
dc.identifier.othervv_1032021
dc.identifier.otherav_60e7879e-7540-4d70-a6f7-cb86080698d3
dc.identifier.urihttp://hdl.handle.net/20.500.12627/67606
dc.identifier.urihttps://doi.org/10.1016/s0168-8278(13)61420-8
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectGastroenteroloji-(Hepatoloji)
dc.titleALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)
dc.typeBildiri
dc.contributor.departmentHospital Universitari Vall d''Hebron , ,
dc.identifier.volume58
dc.contributor.firstauthorID141453


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record